home / stock / srpt / srpt articles

SRPT Articles, Sarepta Therapeutics Inc. - From 02/16/24

Stock Information
Company Name: Sarepta Therapeutics Inc.
Stock Symbol: SRPT
Market: NASDAQ
Website: sarepta.com
Menu
SRPT SRPT Quote SRPT Short SRPT News SRPT Articles SRPT Message Board
Get SRPT Alerts

News, Short Squeeze, Breakout and More Instantly...
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session | Benzinga

Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quart...
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday | Benzinga

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday. Shares of Applied Materials, Inc. (NASDAQ: AMAT) rose sha...

Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst | Benzinga

Last Wednesday,  REGENXBIO Inc (NASDAQ:RGNX) reported additional interim safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE tria...

Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing | Benzinga

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced data from Part B of the MOMENTUM study (Study SRP-5051-201) Phase 2, multi-ascending dose tri...
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year | Benzinga

Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product revenue of $1.145 billion. The Cambridge, Mass...

Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday | Benzinga

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Acuity Brands, Inc. (NYSE: AYI) rose sharply Tuesd...

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 | Benzinga

Needham analyst forecasts a positive outlook for Arcellx Inc (NASDAQ:ACLX) in 2024, citing strong potential stemming from the anticipated pivotal...
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT | Benzinga

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securitie...

Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy | Benzinga

Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the consen...

Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There' | Benzinga

On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got...
Previous 10 Next 10